Travere Therapeutics TVTX
NASDAQ TVTX
$59.99 -1.58 (-2.57%)
At close: Sep 29, 2026 · 4:00 PM EDT

Travere Therapeutics (TVTX) Research & Development (2013 - 2026)

Updated

Travere Therapeutics' Research & Development was $60.28 million in Q2 2026, up 22.1% from $49.36 million a year earlier and up 5.6% from the prior quarter.

Analysis

Travere Therapeutics (TVTX) Research & Development (2013 - 2026) Analysis & Trends

On a trailing twelve-month basis, Travere Therapeutics' Research & Development was $227.14 million through Jun 30, 2026, up 8.2% year-over-year; for FY2025, it came in at $206.01 million, down 5.3% from FY2024.

  • Research & Development shows a five-year compound annual growth rate of 9.3% (FY2020 to FY2025).
  • In earlier years, Research & Development was $217.5 million in FY2024 (-11.2%), $244.99 million in FY2023 (+7.8%), $227.33 million in FY2022 (+13.0%) and $201.16 million in FY2021 (+52.7%).
  • The Q2 2026 figure marks the highest quarterly Research & Development since Q4 2024.
  • Compared with a year earlier, Research & Development was higher in four of the last eight quarters, with growth averaging 1.6%.
  • The best year-over-year quarter for Research & Development over five years was Q3 2021 (growth of 49.6%); the worst was Q2 2024 (a decline of 18.3%).
  • Per Business Quant data, TVTX's Research & Development in the three quarters before Q2 2026 was $57.09 million (Q1 2026), $57.87 million (Q4 2025) and $51.89 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 3.65 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 2.34 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 9.74 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -2.85 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -4.05 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 1.87 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 1.76 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 2.81 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 993.80 Mn
10 Travere Therapeutics 5.80 Bn 5.40 Bn 167.41 Mn 60.28 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 60.28 Mn
Mar 31, 2026 57.09 Mn
Dec 31, 2025 57.87 Mn
Sep 30, 2025 51.89 Mn
Jun 30, 2025 49.36 Mn
Mar 31, 2025 46.89 Mn
Dec 31, 2024 62.07 Mn
Sep 30, 2024 51.68 Mn
Jun 30, 2024 54.33 Mn
Mar 31, 2024 49.42 Mn
Dec 31, 2023 59.75 Mn
Sep 30, 2023 60.59 Mn
Jun 30, 2023 66.49 Mn
Mar 31, 2023 58.16 Mn
Dec 31, 2022 58.09 Mn
Sep 30, 2022 57.15 Mn
Jun 30, 2022 59.68 Mn
Mar 31, 2022 56.61 Mn
Dec 31, 2021 53.00 Mn
Sep 30, 2021 48.41 Mn
API Access

Travere Therapeutics Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=TVTX&period=max&api_key=YOUR_API_KEY